C
OMBINATION ANTIRETROviral therapy (CART) has dramatically reduced human immunodeficiency virus (HIV)-related morbidity and mortality. [1] [2] [3] Current guidelines recommend starting CART at earlier stages of HIV infection and continuing lifelong treatment. [4] [5] [6] However, adverse drug reactions, drug-drug interactions, and comorbidities and socioeconomic barriers may influence the safety and efficacy of CART.
Adverse events have been reported with all antiretroviral drugs and are among the most common reasons for switching or discontinuing therapy and for poor adherence to the medication regimen. [7] [8] [9] [10] [11] [12] In the Swiss HIV Cohort Study (SHCS), the presence of laboratory adverse events was associated with increased mortality during 6 years of follow-up. 13 Treatment-limiting toxic effects in randomized controlled trials appear to be declining with newer antiretroviral regimens, ranging from 3% for individuals treated with combined tenofovir disoproxil fumarate and emtricitabine with atazanavir sulfate 14 to 4% for those receiving combined tenofovir and emtricitabine with efavirenz and 9% for combined zidovudine and lamivudine with efavirenz. 15 However, Vo et al 7 recently reported that up to 40% of patients in the SHCS changed their antiretroviral treatment within the first year after starting CART, half of them because of toxic effects. In that study, rates of treatment modification did not vary from 2000 to 2005, possibly reflecting the increased availability of alternative drugs.
Toxic effects of CART have been associated with demographic characteristics, drugdrug interactions, comorbidities, and, more recently, genetic factors. Patients coinfected with hepatitis B and/or C virus are at increased risk for hepatic events caused by sev-eral antiretroviral drugs, but this association remains controversial. 7, 12, [16] [17] [18] Moreover, the prevalence of adverse events affecting the central nervous system (CNS) during treatment with efavirenz, leading to treatment discontinuation in about 10% to 15% of patients, 19 was related to higher plasma levels 20 and black ethnicity. 21 Knowledge about the genes implicated in pharmacokinetics, mode of action, efficacy,andtoxicityofdrugsprovidesrelevantresultsforclinical practice. For example, the presence of the HLA-B*5701 allele predicts an abacavir sulfate hypersensitivity reaction with potentially severe consequences. 22, 23 This study investigates factors associated with early CART modification owing to drug toxicity in antiretroviralnaive HIV-infected individuals who recently started CART within the SHCS. Specific objectives were to assess the probability of a treatment switch or discontinuation according to the most often recommended and prescribed antiretroviral regimens (ie, nonnucleoside reverse transcriptase inhibitor [NNRTI] vs protease-inhibitor [PI] based, efavirenz vs nevirapine, boosted atazanavir [atazanavir/r], and boosted lopinavir [lopinavir/r]), to explore risk factors of the most common toxic effects (ie, gastrointestinal tract intolerance, hypersensitivity, CNS adverse effects, and hepatic events) leading to a switch or discontinuation of therapy within the first year after starting CART, and to explore the impact of treatment modification on virologic and immunologic outcomes.
METHODS

STUDY DESIGN
We analyzed the SHCS database, 24 a large prospective cohort study with continuous enrollment of HIV-infected individuals 16 years or older. Basic sociodemographic characteristics, data on the clinical course (occurrence of opportunistic infections or death), coinfection with hepatitis B and C viruses, antiretroviral therapy, comedication (prophylaxis and treatment of opportunistic infections, cardiovascular drugs, and treatment of hepatitis C virus and neoplasms), and immunologic and virologic variables are collected at enrollment into the study and every 6 months thereafter on standardized data collection forms. AIDS-defining diseases are recorded using the 1993 revised clinical definition of AIDS from the Centers for Disease Control and Prevention. 25 The cause of death is reported using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision. 26 For the present analysis we used the SHCS database extract of January 2009.
STUDY POPULATION
Antiretroviral-naïve HIV-infected individuals participating in the SHCS who started CART between January 1, 2005, and June 30, 2008, and had a follow-up of at least 6 months were eligible for this study. Pregnant women were excluded from this analysis because drug-related adverse events may affect this population differently, and women initiating CART for prevention of motherto-child transmission often discontinue treatment after delivery.
DEFINITIONS
We defined CART as an antiretroviral regimen containing at least 3 drugs, that is, 2 nucleoside/nucleotide reversetranscriptase inhibitors (NRTIs) in combination with an NNRTI or a PI, or 3 NRTIs. Antiretroviral regimens and the NRTI backbone were classified according to the preferred recommended regimens, 4, 5 that is, boosted atazanavir/r, lopinavir/r, efavirenz, nevirapine, zidovudine/lamivudine, abacavir/lamivudine, tenofovir/emtricitabine, or tenofovir/ lamivudine. We excluded individuals receiving investigational regimens containing CC-chemokine receptor 5 inhibitors or integrase inhibitors.
Treatment modification was defined as a switch or discontinuation of CART within the first year. A switch to another regimen was defined as changing 1 or more drugs within 4 weeks after stopping CART. Discontinuation was defined as stopping any antiretroviral drug for at least 4 weeks. A switch from tenofovir-lamivudine to tenofovir-emtricitabine was not considered a treatment modification because it reflects the delayed availability of the new fixed formulation of tenofoviremtricitabine in Switzerland in 2007. The main reason for treatment modification was classified as treatment failure, intolerance and/or toxic effects, the patient's choice, the physician's decision, and other reasons. Information on drug concentration was used to investigate the occurrence of CNS adverse events in patients with available results.
Virologic suppression was defined as achieving HIV-RNA counts of less than 50 copies/mL at 12 months after starting CART.
STATISTICAL ANALYSIS
The primary end point was the time to the first treatment modification (ie, a switch to another antiretroviral regimen or discontinuation) during the first year after starting CART.
Basic sociodemographic characteristics, CD4 cell count, HIV viral load, and CART were compared using the 2 test or Fisher exact test for categorical variables and the Mann-Whitney test for continuous variables. We used Kaplan-Meier curves to describe the cumulative incidence of treatment modification according to the most frequently recommended first-line antiretroviral regimens, and the curves were compared using log-rank tests. Risk factors of treatment switch or discontinuation within the first year after starting CART were investigated using Cox proportional hazards models. All patients were censored at 1 year after starting CART if no treatment modification or death had occurred.
All analyses were performed using commercially available software (Stata, version 9.2 for Windows; StataCorp, College Station, Texas). per 100 person-years, half of them occurring within the first 3 months. The most frequent reasons for treatment modification were toxic effects (46.6%), followed by a physician's decision (22.8%), the patient's choice (16.9%), and treatment failure (5.9%). Overall, 297 individuals (76.0%) switched to a new antiretroviral regimen within 4 weeks after stopping CART, whereas 94 (24.0%) discontinued CART for at least 4 weeks. Among switchers, 48.8% modified the backbone and the third drug; 43.8%, the third drug only; and 6.4%, the backbone only. The Abbreviations: ABC, abacavir sulfate; ATV/r, boosted atazanavir sulfate; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CART, combined antiretroviral therapy; EFV, efavirenz; FTC, emtricitabine; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; IQR, interquartile range; LPV/r, boosted lopinavir; MSM, male same-sex relationships; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine; PCP, Pneumocystis jiroveci pneumonia; PI, protease inhibitor; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
RESULTS
STUDY POPULATION
a Unless otherwise indicated, data are expressed as number (percentage) of patients. b Includes treatment of neoplasm (n = 18) and coinfection with hepatitis C (n = 12).
outcome in terms of virologic suppression to less than 50 copies/mL at 12 months was similar in individuals switched to another regimen compared with those who did not modify their treatment (87.9% vs 89.2%; P=.90). Similarly, no difference in the median CD4 cell count increase at 12 months was noted among switchers and individuals who did not change their treatment (169/µL vs 170/µL; P = .79). In contrast, patients discontinuing CART for longer than 4 weeks were less likely to achieve virologic suppression to less than 50 copies/mL (47.1%; PϽ .001) and immunologic recovery (median CD4 cell count increase of 107/µL; P = .002). Individuals treated with zidovudine-lamivudine combined with lopinavir/r showed the highest rate of treatment modification (70. (Figure, A) . The probability of treatment modification tended to decrease for efavirenz and lopinavir/r and to increase for atazanavir/r and nevirapine during the study period. In a multivariate analysis (Table 2) , the use of lopinavir/r and zidovudine-lamivudine was associated with higher treatment modification rates, as were female sex, nonwhite ethnicity, a prior AIDS-defining condition, and increasing baseline CD4 cell count.
TREATMENT MODIFICATION ATTRIBUTED TO DRUG INTOLERANCE AND/OR TOXICITY
During the first year of CART, 208 individuals (15.8%) modified their treatment because of drug intolerance and/or drug toxicity, corresponding to 22.4 (95% CI, 19.5-25.6) treatment modifications per 100 person-years, mostly (64.2%) during the first 3 months. No differences in the rate of treatmentlimiting adverse events were observed during the study period (P = .26). Gastrointestinal tract intolerance was the most frequent toxic effect (28.9%), followed by hypersensitivity (18.3%), CNS adverse events (17.3%), and hepatic events (11.5%). The median time to treatment modification varied according to different toxic effects, ranging from 14 (IQR, 10-21) days for hypersensitivity to 66 (28-154) days for gastrointestinal tract intolerance, 72 (28-120) days for hepatic events, and 105 (50-228) days for CNS adverse events. Overall, 182 individuals (87.5%) switched to a new antiretroviral regimen, whereas 26 (12.5%) discontinued CART for at least 4 weeks. A large proportion of individuals achieved virologic suppression to less than 50 copies/mL at 12 months after starting CART regardless of treatment modification (85% vs 87%; P = .56) and the median increase in CD4 cell count was similar in both groups (166/µL vs 171/ µL; P=.94). In contrast, only 58.2% of patients discontinuing CART for longer than 4 weeks achieved HIV-RNA suppression to less than 50 copies/mL at 12 months (P Ͻ .001) and showed a median CD4 cell count increase of 133/µL (P = .02). In general, individuals starting an NNRTI-based regimen were less likely to modify their treatment compared with those treated with a PI (P = .052). The Efavirenz therapy was switched or discontinued mainly because of CNS adverse events (44.4%); lopinavir/r therapy, because of gastrointestinal tract intolerance (52.7%); and nevirapine therapy, after a hypersensitivity reaction (40.7%). The most frequent toxic effects related to the use of atazanavir/r were hepatic events (29.3%) and hypersensitivity (24.6%). In a multivariate analysis ( 
SPECIFIC DRUG INTOLERANCES AND TOXIC EFFECTS
Gastrointestinal Tract Intolerance
Gastrointestinal tract intolerance was the most frequent toxic effect, with 6.3 (95% CI, 4.9-8.1) treatment modifications per 100 person-years, mostly associated with the use of lopinavir/r and zidovudine-lamivudine. In a multivariate analysis, risk factors of gastrointestinal tract intolerance were lopinavir/r and zidovudine-lamivudine, nonwhite ethnicity, and baseline CD4 cell count of more than 350/µL ( (Table 4) .
CNS Adverse Events
The rate of treatment-limiting CNS adverse events was 3.8 (95% CI 2.7-5.2) per 100 person-years, clearly related to the use of efavirenz. In a multivariate analysis, treatment with efavirenz and female sex were independently associated with the occurrence of CNS adverse events (Table 4 ). In 196 patients with an available plasma drug concentration, higher efavirenz plasma levels were linked to higher treatment modification rates (P=.002). After adjustment for age, sex, ethnicity, and body mass index, efavirenz plasma level was the only factor associated with increased rates of treatment switch or discontinuation (P=.008).
Hepatic Events
The rate of treatment modification owing to hepatic events was 2.5 (95% CI 1.7-3.7) per 100 person-years, mainly associated with the use of atazanavir, which is known to cause elevation of indirect bilirubin levels. Treatment with atazanavir/r and comedication for opportunistic infection were independently associated with treatment modification coded as liver-related toxic effects (Table 4) . Coinfection with hepatitis B or C virus did not increase the risk of treatment-related liver injury in this study.
COMMENT
This study, involving 1318 antiretroviral-naive HIVinfected individuals who started CART between January 1, 2005, and June 30, 2008, in a large cohort study, illustrates that drug toxicity remains a frequent prob- lem in clinical practice, accounting for approximately half of all reasons for treatment switch or discontinuation during the first year of CART. Virologic and immunologic outcomes at 12 months were not impaired in individuals with treatment modification regardless of their reasons for change, suggesting that most people can achieve successful suppression using alternative antiretroviral regimens. Further findings of this study describe the toxicitydependent time for treatment modification being the shortest for hypersensitivity and the longest for CNS adverse events. Also, a comparison of regimen-related toxic effects showed that the rate of therapy switch or discontinuation was lowest for patients treated with tenofoviremtricitabine combined with atazanavir/r. These findings are consistent with those from previous SHCS studies 7, 27 and other cohort studies, 8, [10] [11] [12] 17, [28] [29] [30] underlining the importance of close monitoring and adequate management of adverse effects and drug-drug interactions for the durability of CART in clinical practice. The discrepancy with lower treatment discontinuation rates (Ͻ10%) for new antiretroviral drugs reported in randomized clinical trials 14, 15 probably reflects a selection bias because individuals with severe comorbidities are often excluded from clinical trials. On the other hand, the broad availability of new drugs with the possibility of once-daily regimens may have triggered treatment modification, 7, 10, 31 as suggested by the high proportion of patients switched to another antiretroviral regimen in our study. Among antiretroviral drugs, boosted lopinavir and zidovudinelamivudine therapies were most frequently switched or discontinued during the first year of CART. No differences were observed between newer regimens, that is, tenofoviremtricitabine combined with efavirenz or atazanavir/r, or abacavir-lamivudine combined with efavirenz, suggesting that these first-line regimens are suitable for long-term use.
In our study, women and individuals of nonwhite ethnicity were more likely to modify their antiretroviral treatment because of drug toxicity or intolerance. This may be explained by biological differences between the sexes 20 and genetic factors influencing the pharmacokinetics of specific drugs and thus their plasma levels. 18, 21, 32 Also, sociocultural barriers leading to a different perception of drug-related adverse events, as described among vulnerable populations, may play a role. 21, 28, 29, 33, 34 Specific genetic tests can promptly influence treatment modification, as demonstrated in our study by the decreasing discontinuation rates of abacavir therapy after the introduction of screening for HLA-B*5701. 23 As previously reported, 7 higher baseline CD4 cell counts were associated with increased rates of treatment discontinuation, frequently without switching to alternative drugs, suggesting a lower motivation to continue an antiretroviral regimen causing adverse effects in patients with less urgent indication for CART. On the other hand, patients who were treated for a concomitant opportunistic infection (cytomegalovirus, toxoplasmosis, Pneumocystis jiroveci pneumonia, tuberculosis, or atypical mycobacteria) were more likely to modify their treatment as a result of drug-drug interactions and cumulative drug toxicity. In older individuals, a higher incidence of toxic effects may reflect altered pharmacokinetics, impaired drug metabolism, and frequent comedication with a potential for drug-drug interactions. Detailed data on comedication, particularly the use of psychotropic and over-the-counter drugs, were not available for the present analysis; therefore, the confounding role of drug-drug interactions in treatment modification could not be fully assessed. Nevertheless, a recent study of the SHCS on the prevalence and clinical relevance of drug-drug interactions in HIV-infected individuals reported no significant influence on treatment change rates in patients with drug-drug interactions. 35 Coinfection with hepatitis B or C virus was not associated with a higher risk of toxic effects from CART in our study. This is in contrast to data from earlier studies, 12, 17 possibly because of different antiretroviral drugs being used more recently; for example, in our study a very low proportion of patients were treated with didanosine or stavudine, which have been linked to liver injury.
Individualsstartinglopinavir/rcombinedwithzidovudinelamivudine therapy and those with higher CD4 cell counts and therefore less symptomatic HIV disease were at highest risk of gastrointestinal tract intolerance that may compromise quality of life and lead to poor treatment adherence. This is in contrast to other cohort studies, 8, 36 in which gastrointestinal tract adverse events tended to be more common in people with lower CD4 cell counts. This difference may be explained by the higher proportion of patients with advanced HIV disease in earlier studies, where misclassification of gastrointestinal tract intolerance might have occurred because diarrhea, dysphagia, and weight loss are frequently associated with opportunistic infections. 37 A hypersensitivity reaction was most likely in women with a higher baseline CD4 cell count who were treated with nevirapine. Severe hepatic events ranging from skin rash to StevensJohnsonsyndromehavebeenobservedduringthefirstweeks of treatment when nevirapine therapy was initiated in antiretroviral-naive women with a CD4 cell count of more than 250/µL. 18, 38, 39 For these patients, alternative regimens should be chosen. 6 Treatment-limiting hepatic events were mainly noted in individuals receiving atazanavir/r and a comedication. Atazanavir is known to cause reversible elevation of unconjugated bilirubin levels by competitive inhibition of the uridine diphosphate glucuronosyltransferase UGT1A1 in up to 50% of patients. Jaundice is more likely to develop in individuals homozygous for the UGT1A1*28 allele. 40 In this context, treatment modification was probably related to the occurrence of jaundice and not to liver injury. However, the need of comedication, particularly concomitant treatment of opportunistic infections, may cause drug-drug interactions, leading to an increase in transaminase levels and thus treatment modification. 41, 42 Finally, CNS adverse events were linked to an efavirenz-containing regimen and were more frequently reported by women. However, in 196 individuals with available efavirenz plasma concentrations, after adjustment for age, sex, ethnicity, and body mass index, the efavirenz plasma level was the only factor associated with higher modification rates, suggesting that sex differences result from different drug concentrations and that women may benefit from closer monitoring and dose adjustment of efavirenz. 20 The strengths of this study were the high number of patients treated with newer antiretroviral regimens according to recent guidelines and the availability of co-medication data that included treatment of opportunistic infection and use of cardiovascular drugs. We acknowledge some limitations. Misclassification of the reason for treatment modification may have occurred because many factors may play a role in decision making. In particular, no code for treatment simplification exists in the SHCS as a reason for stopping a specific drug therapy, although these individuals have probably received codes indicating the reason as being the patient's choice or the physician's decision. Toxic effects of CART were investigated by the occurrence of treatment modification, but alterations in laboratory variables (renal and liver function and bilirubin level) were not checked. Moreover, some adverse events may be difficult for patients to understand and report. It is therefore possible that the overall occurrence of drug-related adverse effects has been underestimated. As stated, information on comedications was not complete because information on psychotropic and over-the-counter drugs was not collected in the SHCS database. In addition, data on treatment adherence were not considered for the present analysis. Also, therapeutic drug monitoring was not performed routinely, except for special indications, mainly if treatment toxicity or treatment nonadherence was clinically suspected.
In conclusion, high rates of CART switch remain a major issue in clinical practice. The availability of different treatment options may trigger CART modification within the first weeks and months. If treatment is modified, this is done early and, as shown in our study, does not compromise CART outcome. Further research should address whether, with wider testing of toxicity-related factors (eg, genes associated with toxicity), first-line treatment regimens will be more robust in terms of durability.
